Coherus Biosciences Share Price (NASDAQ: CHRS)

$1.12

▲

0.05

(4.67%)

Live

Last updated on August 22, 2025 at 12:37 AM IST

$₹

Check the interactive Coherus Biosciences Stock chart to analyse performance

Coherus Biosciences stock performance

as on August 22, 2025 at 12:37 AM IST

Today's Low:$1.06
Today's High:$1.15
$1.12
5.36%
Downside
Day's Volatility :7.42%
Upside
2.18%
52 Weeks Low:$0.66
52 Weeks High:$2.43
$1.12
41.04%
Downside
52 Weeks Volatility :72.83%
Upside
53.91%

Coherus Biosciences Stock Returns

Period	Coherus Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	37.4%	4.5%	0.0%
6 Months	-3.18%	-6.1%	0.0%
1 Year	-20.52%	-11.1%	0.0%
3 Years	-91.36%	3.4%	-9.6%

Coherus Biosciences Inc Key Stats

Check Coherus Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.07
Open	$1.06
Today's High	$1.145
Today's Low	$1.06
Market Capitalization	$124.4M
Today's Volume	$1.2M
52 Week High	$2.43
52 Week Low	$0.6603
Revenue TTM	$272.2M
EBITDA	$-83.8M
Earnings Per Share (EPS)	$0.53
PE Ratio	2.02
Profit Margin	66.03%
Quarterly Earnings Growth YOY	-0.75%
Return On Equity TTM	33.11%

Stock Returns calculator for Coherus Biosciences Stock including INR - Dollar returns

The Coherus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Coherus Biosciences investment value today

Current value as on today

₹87,509

Returns

₹12,491

(-12.49%)

Returns from Coherus Biosciences Stock

₹16,418 (-16.42%)

Dollar Returns*

₹3,927 (+3.93%)

Indian investors sentiment towards Coherus Biosciences Stock

-18%

Period: Jul 21, 2025 to Aug 20, 2025. Change in 30 Days versus previous period

Search interest for Coherus Biosciences Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Coherus Biosciences Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
9.45%
Vanguard Group Inc
9.09%
Rubric Capital Management LP
4.52%
TANG CAPITAL MANAGEMENT LLC
4.39%
Kohlberg Kravis Roberts & Co LP
2.61%
Millennium Management LLC
2.50%

Analyst Recommendation on Coherus Biosciences Stock

Rating

Trend

Buy

81%Buy

18%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Coherus Biosciences(by analysts ranked 0 to 5 stars)

Coherus Biosciences Share Price Target

What analysts predicted

Upside of 319.64%

Target:

$4.70

Current:

$1.12

Coherus Biosciences share price target is $4.70, a slight Upside of 319.64% compared to current price of $1.12 as per analysts' prediction.

Coherus Biosciences Stock Insights

Price Movement
In the last 7 days, CHRS stock has moved up by 4.4%
Increasing Revenue
Revenue is up for the last 2 quarters, 7.59M → 10.25M (in $), with an average increase of 25.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -56.56M → 297.76M (in $), with an average increase of 119.0% per quarter
CHRS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.1% return, outperforming this stock by 84.6%
CHRS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.1% return, outperforming this stock by 203.7%
Price to Sales
ForCHRS every $1 of sales, investors are willing to pay $0.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.1 for every $1 of sales.

Coherus Biosciences Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$356.1M	↑ 22783.74%
Net Income	$89.8M	↓ 142.91%
Net Profit Margin	25.23%	↑ 13478.89%

	FY20	Y/Y Change
Revenue	$475.8M	↑ 33.63%
Net Income	$132.2M	↑ 47.21%
Net Profit Margin	27.79%	↑ 2.56%

	FY21	Y/Y Change
Revenue	$326.6M	↓ 31.37%
Net Income	$-287.1M	↓ 317.1%
Net Profit Margin	-87.92%	↓ 115.71%

	FY22	Y/Y Change
Revenue	$211.0M	↓ 35.37%
Net Income	$-291.8M	↑ 1.62%
Net Profit Margin	-138.24%	↓ 50.32%

	FY23	Y/Y Change
Revenue	$257.2M	↑ 21.89%
Net Income	$-237.9M	↓ 18.46%
Net Profit Margin	-92.48%	↑ 45.76%

	FY24	Y/Y Change
Revenue	$267.0M	↑ 3.78%
Net Income	$28.5M	↓ 111.98%
Net Profit Margin	10.68%	↑ 103.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$2.3M	↓ 97.48%
Net Income	$102.9M	↓ 229.15%
Net Profit Margin	4.5K%	↑ 4544.35%

	Q2 FY24	Q/Q Change
Revenue	$65.0M	↑ 2715.38%
Net Income	$-12.9M	↓ 112.56%
Net Profit Margin	-19.88%	↓ 4477.2%

	Q3 FY24	Q/Q Change
Revenue	$70.8M	↑ 8.92%
Net Income	$-10.8M	↓ 16.79%
Net Profit Margin	-15.19%	↑ 4.69%

	Q4 FY24	Q/Q Change
Revenue	$54.1M	↓ 23.5%
Net Income	$-50.7M	↑ 371.55%
Net Profit Margin	-93.63%	↓ 78.44%

	Q1 FY25	Q/Q Change
Revenue	$7.6M	↓ 85.97%
Net Income	$-56.6M	↑ 11.58%
Net Profit Margin	-744.43%	↓ 650.8%

	Q2 FY25	Q/Q Change
Revenue	$10.3M	↑ 34.94%
Net Income	$297.8M	↓ 626.38%
Net Profit Margin	2.9K%	↑ 3648.34%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$339.0M	↓ 20290.17%

	FY20	Y/Y Change
Profit	$438.2M	↑ 29.25%

	FY21	Y/Y Change
Profit	$269.0M	↓ 38.62%

	FY22	Y/Y Change
Profit	$141.0M	↓ 47.59%

	FY23	Y/Y Change
Profit	$98.3M	↓ 30.3%

	FY24	Y/Y Change
Profit	$149.4M	↑ 52.07%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$41.0M	↑ 595.11%

	Q2 FY24	Q/Q Change
Profit	$35.4M	↓ 13.54%

	Q3 FY24	Q/Q Change
Profit	$50.0M	↑ 41.24%

	Q4 FY24	Q/Q Change
Profit	$20.3M	↓ 59.45%

	Q1 FY25	Q/Q Change
Profit	$4.9M	↓ 75.62%

	Q2 FY25	Q/Q Change
Profit	$5.8M	↑ 18.14%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$28.4M	↓ 117.8%
Investing Cash Flow	$-12.7M	↑ 971.72%
Financing Cash Flow	$89.4M	↓ 15.23%

	FY20	Y/Y Change
Operating Cash Flow	$154.1M	↑ 443.63%
Investing Cash Flow	$-14.4M	↑ 13.11%
Financing Cash Flow	$223.9M	↑ 150.58%

	FY21	Y/Y Change
Operating Cash Flow	$-37.4M	↓ 124.28%
Investing Cash Flow	$-138.4M	↑ 861.11%
Financing Cash Flow	$51.9M	↓ 76.83%

	FY22	Y/Y Change
Operating Cash Flow	$-241.1M	↑ 544.17%
Investing Cash Flow	$-166.9M	↑ 20.55%
Financing Cash Flow	$54.3M	↑ 4.72%

	FY23	Y/Y Change
Operating Cash Flow	$-174.9M	↓ 27.47%
Investing Cash Flow	$144.6M	↓ 186.69%
Financing Cash Flow	$69.6M	↑ 28.12%

	FY24	Y/Y Change
Operating Cash Flow	$-20.4M	↓ 88.31%
Investing Cash Flow	$230.3M	↑ 59.24%
Financing Cash Flow	$-187.0M	↓ 368.64%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-46.8M	↑ 261.49%
Investing Cash Flow	$202.8M	↑ 475.98%
Financing Cash Flow	$887.0K	↑ 142.35%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$59.7M	↓ 227.73%
Investing Cash Flow	$27.7M	↓ 86.36%
Financing Cash Flow	$-187.9M	↓ 21286.58%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-62.0M	↓ 203.82%
Investing Cash Flow	$444.0K	↓ 98.39%
Financing Cash Flow	$-167.0K	↓ 99.91%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$28.6M	↓ 146.13%
Investing Cash Flow	$-542.0K	↓ 222.07%
Financing Cash Flow	$231.0K	↓ 238.32%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-25.8M	↓ 190.28%
Investing Cash Flow	$-17.5M	↑ 3126.2%
Financing Cash Flow	$-264.0K	↓ 214.29%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-46.6M	↑ 80.56%
Investing Cash Flow	$462.6M	↓ 2745.76%
Financing Cash Flow	$-281.5M	↑ 106537.88%

Coherus Biosciences Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Coherus Biosciences Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Coherus Biosciences Inc	15.47%	-3.18%	-20.52%	-91.36%	-94.42%
Regeneron Pharmaceuticals, Inc.	5.39%	-15.07%	-50.13%	-3.42%	-0.61%
Beone Medicines Ltd	4.61%	26.63%	56.19%	78.75%	30.26%
Vertex Pharmaceuticals Incorporated	-16.11%	-17.89%	-18.87%	34.22%	47.47%
Alnylam Pharmaceuticals, Inc.	40.82%	82.49%	64.08%	110.21%	247.67%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Coherus Biosciences Inc	2.02	2.02	0.0	-1.31	0.33	-0.1	NA	1.03
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Coherus Biosciences Inc	Buy	$124.4M	-94.42%	2.02	66.03%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-0.61%	14.47	31.37%
Beone Medicines Ltd	NA	$38.5B	30.26%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	47.47%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	247.67%	NA	-12.96%

About Coherus Biosciences Inc

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Organization	Coherus Biosciences
Employees	177
CEO	Mr. Dennis M. Lanfear
Industry	Health Technology

Key Management of Coherus Biosciences Inc

Name	Title
Mr. Dennis M. Lanfear	Chairman, President & CEO
Mr. Bryan J. McMichael	Chief Financial Officer
Ms. Jodi Sievers	Vice President of Investor Relations & Corporate Communications
Mr. Andy Rittenberg	Executive Vice President of General Counsel
Mr. Scott Saywell	Executive Vice President of Corporate Development
Ms. Rebecca Sunshine	Chief Human Resources Officer
Mr. Michael Chen	Senior Vice President of Commercial Analytics & Trade
Dr. Theresa M. Lavallee Ph.D.	Chief Development Officer & Chairman of Scientific Advisory Board
Dr. Rosh Dias M.D., MRCP	Chief Medical Officer

Important FAQs about investing in CHRS Stock from India :

What is Coherus Biosciences share price today?

Coherus Biosciences share price today is $1.12 as on August 22, 2025 at 12:37 AM IST. Coherus Biosciences share today touched a day high of $1.15 and a low of $1.06.

What is the 52 week high and 52 week low for Coherus Biosciences share?

Coherus Biosciences share touched a 52 week high of $2.43 and a 52 week low of $0.66. Coherus Biosciences stock price today i.e. August 22, 2025 at 12:37 AM IST is trending at $1.12, lower by 53.91% versus the 52 week high.

How to invest in Coherus Biosciences Stock (CHRS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Coherus Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Coherus Biosciences Shares that will get you 1.3393 shares as per Coherus Biosciences share price of $1.12 per share as on August 22, 2025 at 12:37 AM IST.

What is the minimum amount required to buy Coherus Biosciences Stock (CHRS) from India?

Indian investors can start investing in Coherus Biosciences (CHRS) shares with as little as ₹87.2 or $1 (as of August 21, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹872.00 in Coherus Biosciences stock (as per the Rupee-Dollar exchange rate as on August 21, 2025). Based on Coherus Biosciences share’s latest price of $1.12 as on August 22, 2025 at 12:37 AM IST, you will get 8.9286 shares of Coherus Biosciences. Learn more about fractional shares .

What are the returns that Coherus Biosciences has given to Indian investors in the last 5 years?

Coherus Biosciences stock has given -94.42% share price returns and 17.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?